Overall, alterations in the levels of α2-AR and BDNF are closely associated with mood dysregulation, including PPD, with dexmedetomidine showing promise in the regulation of pathophysiological changes in depression as well as possible treatment efficacy in PPD. The gene discussed is ADORA2A; the disease is major depressive disorder.